- Home
- TOI vs DRRX Comparison
TOI vs DRRX Comparison
Compare TOI & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- DRRX
- Stock Information
- Founded
- TOI 2007
- DRRX 1998
- Country
- TOI United States
- DRRX United States
- Employees
- TOI N/A
- DRRX N/A
- Industry
- TOI Medical/Nursing Services
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- TOI Health Care
- DRRX Health Care
- Exchange
- TOI Nasdaq
- DRRX Nasdaq
- Market Cap
- TOI 22.6M
- DRRX 26.4M
- IPO Year
- TOI N/A
- DRRX 2000
- Fundamental
- Price
- TOI $0.55
- DRRX $0.85
- Analyst Decision
- TOI Strong Buy
- DRRX Buy
- Analyst Count
- TOI 1
- DRRX 2
- Target Price
- TOI $2.50
- DRRX $5.00
- AVG Volume (30 Days)
- TOI 951.7K
- DRRX 124.4K
- Earning Date
- TOI 11-13-2024
- DRRX 11-13-2024
- Dividend Yield
- TOI N/A
- DRRX N/A
- EPS Growth
- TOI N/A
- DRRX N/A
- EPS
- TOI N/A
- DRRX N/A
- Revenue
- TOI $378,933,000.00
- DRRX $8,594,000.00
- Revenue This Year
- TOI $29.17
- DRRX $54.32
- Revenue Next Year
- TOI $16.43
- DRRX N/A
- P/E Ratio
- TOI N/A
- DRRX N/A
- Revenue Growth
- TOI 22.29
- DRRX N/A
- 52 Week Low
- TOI $0.13
- DRRX $0.68
- 52 Week High
- TOI $2.45
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- TOI 84.45
- DRRX 47.88
- Support Level
- TOI $0.25
- DRRX $0.79
- Resistance Level
- TOI $0.50
- DRRX $0.86
- Average True Range (ATR)
- TOI 0.07
- DRRX 0.08
- MACD
- TOI 0.02
- DRRX 0.01
- Stochastic Oscillator
- TOI 81.46
- DRRX 51.69
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .